Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
05/03/2012 | 08:11pm CEST

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.

The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012

This information is provided by RNS
The company news service from the London Stock Exchange
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
09/21 GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Provide New Data on Drug Deve..
09/21 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc in the Area of Chemical Biol..
09/21 AGENUS : GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Una..
09/21 GLAXOSMITHKLINE : UK Trade Minister visits GSK Pakistan
09/21 GLAXOSMITHKLINE : 11% Potential Upside Indicated by Deutsche Bank
09/20 GLAXOSMITHKLINE : GSK's new triple lung drug beats other modern inhalers in stud..
09/20DJGLAXOSMITHKLINE : Announces Positive Results for Triple-Therapy Inhaler
09/20 GLAXOSMITHKLINE : Positive IMPACT results for Trelegy in COPD
09/20 GLAXOSMITHKLINE : GSK and Innoviva Report Positive Headline Results from IMPACT ..
09/19 GLAXOSMITHKLINE : FDA OKs Glaxo's inhaler, first one to combine 3 medicines
More news
News from SeekingAlpha
09/25 Hurricane Lessons
09/25 Alnylam And Sanofi Achieve An RNAi First
09/24 J&J : Thoughts On Sirukumab And Other Problems
09/21 FDA's Woodcock says clinical trials system "broken"
09/20 'Safer' Dividend Follower Favorites And Rogues Led By Capitala Finance
Financials ( GBP)
Sales 2017 30 232 M
EBIT 2017 8 500 M
Net income 2017 4 195 M
Debt 2017 14 079 M
Yield 2017 5,43%
P/E ratio 2017 19,13
P/E ratio 2018 15,41
EV / Sales 2017 2,86x
EV / Sales 2018 2,78x
Capitalization 72 499 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,2  GBP
Spread / Average Target 17%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633